Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis
- 1 September 2003
- journal article
- Published by Elsevier in Kidney International
- Vol. 64 (3) , 857-863
- https://doi.org/10.1046/j.1523-1755.2003.00191.x
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Effect of combining ACE inhibitor and statin in severe experimental nephropathyKidney International, 2002
- Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosisKidney International, 2002
- Progression, remission, regression of chronic renal diseasesThe Lancet, 2001
- Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonistsKidney International, 2000
- Pathophysiology of Progressive NephropathiesNew England Journal of Medicine, 1998
- Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathyKidney International, 1998
- The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonistAmerican Journal of Kidney Diseases, 1997
- Chronic Inhibition of Nitric Oxide Synthase in Heymann NephritisNephron, 1996
- Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.Journal of Clinical Investigation, 1986
- Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.Journal of Clinical Investigation, 1986